- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00749060
Comparison of Balloon Kyphoplasty, Vertebroplasty and Conservative Management in Acute Osteoporotic Vertebral Fractures (OSTEO-6)
December 13, 2014 updated by: Assistance Publique - Hôpitaux de Paris
Prospective Randomized Comparative Study of Balloon Kyphoplasty,Vertebroplasty and Conservative Management in Acute Osteoporotic Vertebral Fractures of Less Than 6 Weeks
This study aims to compare three treatments in recent (less than 6 week duration) non-traumatic ( usually osteoporotic) vertebral fractures.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The three treatments are the following: 1/Conventional medical treatment including rest and pain medications2/Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance.3/Balloon
Kyphoplasty which consists of placing through a percutaneous posterior approach under radiological guidance, into the fractured vertebra a balloon which is inflated with fluid and creates a cavity.
This may restore part of the vertebral height loss due to the fracture.
In addition, after balloon deflation, polymethylmetacrylate cement may be injected with low pressure into the created cavity.
The study will indicate if balloon kyphoplasty is able to restore vertebral height of the fractured vertebra better than medical treatment and vertebroplasty.
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France, 75010
- Hopital LARIBOISIERE Service de Radiologie Ostéo-Articulaire
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient is able to undergo the vertebroplasty or Balloon kyphoplasty procedure
- Patient must have signed the consent form (ZELEN Randomization protocol)
- Male or female, 50 years or older
One or two non-traumatic vertebral fracture(s):
- Of osteoporotic origin (low speed trauma such as fall from his own height or less than 80 cm)
- Fracture(s) of less than 6 weeks duration after the onset of pain related to the fracture The fracture(s) exhibit(s) high signal intensity on T2-weighted images and a benign appearance at MRI
- The patient will be able to receive the selected protocol treatment within 6 weeks after onset of fracture-related symptoms and within 15 days after treatment randomization.
- The benign nature of the vertebral fracture has to be confirmed by the results of the biopsy performed during vertebroplasty or balloon kyphoplasty or by one year follow-up in the conservative treatment group.
Exclusion Criteria:
- Patient with a vertebral fracture of more than 6 week duration after onset of fracture-related symptoms.
- Neurological signs related to the vertebral fracture to treat
- History of surgical or percutaneous spine treatment except simple discectomy at a single or multiple vertebral levels with no residual pain.
- More than two recent vertebral fractures
- Current infection
- Impossibility to perform the percutaneous approach of the vertebra to treat.
- Reduction by more than 50% of the anteroposterior width of the bony spinal canal due to the vertebral fracture to treat.
- Known allergy to a contrast media or to one of the cement components used for kyphoplasty.
- Vertebral fracture with loss of 90%or more of the vertebral body height
- Neurological signs or symptoms related to the vertebral fracture
- Malignant and traumatic vertebral fractures
Contraindication to MRI :
- Metallic implant : pace-maker, non movable auditive implant, metallic vascular or cardiac device
- Metallic surgical clips
- Claustrophobia
- Evolutive cardiac disease nonreactive to medical treatment
- Patient presenting a non correctable spontaneous or therapeutic coagulation disorder.
- Presence of an unexplained biological inflammatory syndrome with NFS≥20
- Non compliant patient: Impossibility to participate to the study and to be followed up for 1 year.
- Pregnant or breast feeding women
- Patient not affiliated to social security
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 1
conventional treatment
|
with our without brace
Other Names:
|
Other: 2
kyphoplasty by balloons
|
Balloon Kyphoplasty which consists of placing through a percutaneous posterior approach under radiological guidance, into the fractured vertebra a balloon which is inflated with fluid and creates a cavity.
This may restore part of the vertebral height loss due to the fracture.
In addition, after balloon deflation, polymethylmetacrylate cement is injected with low pressure into the created cavity.
|
Other: 3
vertebroplasty
|
Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Vertebral Kyphotic angle between preoperative and one-year follow-up measurements.
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Intensity of signal with T2 sequence
Time Frame: preoperative and at J360
|
preoperative and at J360
|
Analgesics intake according to the WHO classification (Classes 1, 2 and 3).
Time Frame: J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
Regional spine Kyphosis angle and global thoracic and lumbar Kyphosis angle
Time Frame: J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
Changes in anterior, mid and posterior vertebral heights of the treated vertebral body
Time Frame: J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
Changes in height of the intervertebral disc spaces adjacent to the treated vertebra
Time Frame: J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
1° - Pain evaluation using a visual analogic scale
Time Frame: J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
questionnaire (Eifel) for back pain evaluation
Time Frame: J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
Quality of life evaluation (QUALEFFO - Short-Form SF12).
Time Frame: J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
Number of new vertebral fractures occurring during the one year follow-up period
Time Frame: J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
Cost evaluation in a sample of 10% of patients randomly selected including the following costs : o Intervention cost. o Medical treatment costs o Consultation costs. o Hospitalization cost o Complication costs
Time Frame: J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
J-20 à J-7 / J6 / J45 /J90 /J180 / J360
|
Follow-up of anterior, median and posterior height of the treated vertebral body, obtained by making an average of all measurements, on 3 cuts tomodensitometry (tdm) on the sagittal level : lateral right, median and lateral left
Time Frame: preoperative, at J6 and at J360
|
preoperative, at J6 and at J360
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Jean-Denis LAREDO, MD,Pr, AP-HP Assistance Publique- Hôpitaux de Paris
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2007
Primary Completion (Actual)
June 1, 2012
Study Completion (Actual)
June 1, 2012
Study Registration Dates
First Submitted
September 8, 2008
First Submitted That Met QC Criteria
September 8, 2008
First Posted (Estimate)
September 9, 2008
Study Record Updates
Last Update Posted (Estimate)
December 16, 2014
Last Update Submitted That Met QC Criteria
December 13, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P060107
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporotic Vertebral Fracture
-
Optimus Clinical ResearchCareFusionCompletedVertebral Compression Fractures | Osteoporotic Vertebral Compression Fractures | Acute Vertebral FracturesAustralia
-
Icahn School of Medicine at Mount SinaiRecruitingVertebral Compression Fractures | Osteoporotic Vertebral Compression FracturesUnited States
-
Shenzhen People's HospitalCompletedOsteoporotic Vertebral Compression FractureChina
-
Wiltrom Co., Ltd.Maxis Medical GmbHRecruitingOsteoporotic Vertebral Compression FracturesGermany
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingPrediction Model | Osteoporotic Vertebral FractureChina
-
Inbo HanEnrolling by invitationOsteoporotic Fractures | Vertebral Compression FractureKorea, Republic of
-
Fondation Hôpital Saint-JosephCompletedOsteoporotic FracturesFrance
-
University Hospital, Strasbourg, FranceUnknownVertebral Compression Fractures in Osteoporotic PatientsFrance
-
University Hospital, BonnUnknownOsteoporotic Vertebral Compression Fractures | Lung FunctionGermany
-
Stryker InstrumentsTalosixActive, not recruiting
Clinical Trials on vertebroplasty
-
Centre Leon BerardTerminated
-
University of BernSonnenhof Hospital, BernTerminatedOsteoporosis | Vertebral FractureSwitzerland
-
Centre Leon BerardTerminatedSolid Tumors | Spine MetastasisFrance
-
Li MinRecruiting
-
Spine Centre of Southern DenmarkRecruitingMultiple Myeloma | Vertebral FractureDenmark
-
Optimus Clinical ResearchCareFusionCompletedVertebral Compression Fractures | Osteoporotic Vertebral Compression Fractures | Acute Vertebral FracturesAustralia
-
McGill University Health Centre/Research Institute...UnknownPain | Breast Cancer | Prostate Cancer | Vertebral MetastasisCanada
-
Spine Centre of Southern DenmarkRecruitingVertebral Fracture | Osteoporotic FracturesDenmark
-
University Hospital of PatrasSt. Andrew's General Hospital, Patras, GreeceCompletedThoracic Fracture | Lumbar Fracture
-
Centre Hospitalier Universitaire de NiceCompletedVertebral Fracture | Vertebral TraumaFrance